Table 2. Stratified analyses of the -607C/A polymorphisms in IL-18 gene promoter with cancer risk.
A vs. C |
AA vs. CC |
CA vs. CC |
AA vs. CC/CA
|
AA/CA vs. CC |
|||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Study | OR(95% CI) | Phet | Study | OR(95% CI) | Phet | Study | OR(95% CI) | Phet | Study | OR(95% CI) | Phet | Study | OR(95% CI) | Phet | |
Overall | 23 | 1.088 (0.987-1.200) | 0.003 | 23 | 1.139 (0.948-1.369) | 0.023 | 23 | 1.221 (1.096-1.360)* | 0.219 | 23 | 0.995 (0.851-1.163) | 0.025 | 23 | 1.203 (1.057-1.369)* | 0.064 |
Ethnicity | |||||||||||||||
Asian | 17 | 1.107 (0.972-1.260) | 0.001 | 17 | 1.196 (0.936-1.530) | 0.007 | 17 | 1.191 (1.047-1.356)* | 0.487 | 17 | 1.035 (0.854-1.255) | 0.011 | 17 | 1.197(1.023,1.401)* | 0.088 |
Caucasian | 5 | 1.041 (0.909-1.193) | 0.336 | 5 | 1.023 (0.779-1.343) | 0.473 | 5 | 1.294 (0.906-1.848) | 0.041 | 5 | 0.890 (0.696-1.138) | 0.620 | 5 | 1.198 (0.888-1.618) | 0.083 |
African | 1 | 1.076 (0.790-1.464) | NA | 1 | 1.065 (0.558-2.030) | NA | 1 | 1.578 (0.951-2.620) | NA | 1 | 0.793 (0.455-1.382) | NA | 1 | 1.421 (0.877-2.301) | NA |
Source of controls | |||||||||||||||
Hospital based | 9 | 1.247 (1.022-1.523)* | 0.005 | 9 | 1.329 (0.924-1.912) | 0.009 | 9 | 1.353 (1.115-1.642)* | 0.435 | 9 | 1.135 (0.871-1.479) | 0.044 | 9 | 1.362(1.134,1.635)* | 0.116 |
Population based | 14 | 1.021 (0.941-1.107) | 0.124 | 14 | 1.012 (0.832-1.231) | 0.196 | 14 | 1.165 (1.024-1.327)* | 0.189 | 14 | 0.911 (0.764-1.087) | 0.154 | 14 | 1.114(0.986,1.258) | 0.190 |
Sample size | |||||||||||||||
Small | 18 | 1.092 (0.955-1.249) | <0.001 | 18 | 1.149 (0.896-1.472) | 0.008 | 18 | 1.223 (1.036-1.445)* | 0.085 | 18 | 1.006 (0.813-1.246) | 0.008 | 18 | 1.200 (1.006-1.430)* | 0.016 |
Large | 5 | 1.032 (0.918-1.161) | 0.269 | 5 | 1.051 (0.836-1.320) | 0.313 | 5 | 1.134 (0.863-1.490) | 0.042 | 5 | 0.980 (0.824-1.164) | 0.810 | 5 | 1.107 (0.862-1.421) | 0.052 |
Cancer types | |||||||||||||||
Prostate cancer | 2 | 0.993 (0.852-1.157) | 0.385 | 2 | 0.993 (0.732-1.346) | 0.331 | 2 | 1.039 (0.639-1.690) | 0.081 | 2 | 0.985 (0.773-1.254) | 0.896 | 2 | 1.027 (0.675-1.565) | 0.109 |
Esophageal cancer | 2 | 1.095 (0.926-1.293) | 0.852 | 2 | 1.111 (0.799-1.544) | 0.783 | 2 | 1.371 (1.045-1.800)* | 0.528 | 2 | 0.945 (0.713-1.253) | 0.591 | 2 | 1.289 (1.002-1.658)* | 0.700 |
Nasopharyngeal carcinoma | 4 | 1.144 (0.985-1.328) | 0.845 | 4 | 1.305 (0.961-1.772) | 0.759 | 4 | 1.330 (1.029-1.719)* | 0.704 | 4 | 1.082 (0.842-1.391) | 0.547 | 4 | 1.323 (1.037-1.687)* | 0.823 |
Colorectal cancer | 3 | 1.066 (0.883-1.286) | 0.262 | 3 | 1.092 (0.664-1.795) | 0.213 | 3 | 1.460 (0.898-2.371) | 0.097 | 3 | 0.896 (0.638-1.259) | 0.359 | 3 | 1.337 (0.865-2.068) | 0.118 |
Breast cancer | 2 | 1.147 (0.904-1.456) | 0.726 | 2 | 1.332 (0.800-2.216) | 0.438 | 2 | 1.169 (0.814-1.678) | 0.532 | 2 | 1.225 (0.716-2.096) | 0.274 | 2 | 1.204 (0.854-1.696) | 0.784 |
Cervical cancer | 2 | 1.396 (0.208-9.382) | <0.001 | 2 | 1.890 (0.069-51.901) | <0.001 | 2 | 1.397 (0.644-3.031) | 0.241 | 2 | 1.403 (0.090-21.882) | <0.001 | 2 | 1.653 (0.241-11.339) | 0.003 |
Other cancers | 8 | 1.044 (0.910-1.196) | 0.200 | 8 | 0.978 (0.717-1.334) | 0.223 | 8 | 1.100 (0.803-1.507) | 0.014 | 8 | 0.935 (0.738-1.183) | 0.804 | 8 | 1.075 (0.795-1.454) | 0.012 |
OR: odds ratio; CI: confidence intervals; Phet: P value for heterogeneity; * OR with statistical significance